Stock Watch: Swelling Obesity Sales Boost Post-Pandemic Diabetes Drug Growth
Therapeutic Diabetic Franchises Have Been Transformed
The evolution of new drugs to treat diabetes has enabled some diabetes franchises to shrug off biosimilar competition to insulins. But is some of the growth of therapies for diabetes and obesity a result of the pandemic?
